# US 2012/0251503 A1 · Methods of using chimeric coiled-coil molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251503 A1
- Document ID: US20120251503A1
- Status: Published application
- Kind: A1
- Application number: 13/474,439
- Filed: 2012-05-17
- Published: 2012-10-04
- Earliest claimed: 2007-03-27
- Assignees: Aprogen, Inc.
- Inventors: Gou Young KOH; Chung-Hyun Cho
- Web page: https://patentgrep.com/patent/US20120251503A1

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61P 3/06: Antihyperlipidemics
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 15/10: for impotence
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- C07K 14/515: Angiogenesic factors; Angiogenin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

## Claims

### Claim 1

A coiled coil chimeric molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

### Claim 2 (depends on 1)

A method of treating an ischemic disease comprising administering to a person in need thereof an effective amount of the molecule according to claim 1.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the coiled coil domain comprises a domain belonging to a protein belonging to matrix protein family, transcription factor family, growth factor family or secretory protein family.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the coiled coil domain is from cartilage matrix protein or cartilage oligomeric matrix protein.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the receptor binding domain binds to Tie 1 or Tie2.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the ligand is a cytokine, hormone or growth factor.

### Claim 7 (depends on 6)

The method of claim 6, wherein the ligand is angiopoietin-1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the chimeric coiled coil molecule is COMP-Ang1.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the ischemic disease is of the heart, limb, brain, penis, stomach or kidney.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the chimeric coiled coil molecule is administered in its protein form.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the protein is in form for topical administration.

### Claim 12 (depends on 2)

The method according to claim 2, wherein the chimeric coiled coil molecule is administered in gene construct form within a delivery vehicle.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the delivery vehicle is a virus.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the delivery vehicle is adenovirus.

### Claim 15 (depends on 1)

A method of healing wound comprising administering to a person in need thereof an effective amount of the molecule according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the wound is cutaneous or internal to the body, or severe burns.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the wound is on a person suffering from diabetes.

### Claim 18 (depends on 1)

A method for treating vascular leakage comprising administering to a person in need thereof an effective amount of the molecule according to claim 1.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the vascular leakage is due to sepsis, diabetic retinopathy, brain edema, excessive hemorrhagia, menorrhagia or nasal bleeding.

### Claim at position 20

20-21. (canceled)

### Claim 22 (depends on 1)

A method for treating myocardial infarction comprising administering to a person in need thereof an effective amount of the molecule according to claim 1.
